Leading the Indian pharmaceutical sector and making a name for itself internationally is Sun Pharma. It offers a wide range of medications in its portfolio and a robust pipeline of new ones in a number of therapeutic fields, including oncology, gastrointestinal, cardiology, and neurology. Sun Pharma has grown its presence in more than 100 nations over the years and has become a top choice for research and development partnerships with top international pharmaceutical businesses.
Future investors and stakeholders are very interested in the share price of Sun Pharma. The demand for high-quality medications and treatments is anticipated to rise as the healthcare sector is predicted to expand dramatically. Sun Pharma has a fantastic chance to use its experience in this situation.
CLICK HERE TO KNOW:
UCO BANK SHARE PRICE TARGET 2023 TO 2030: CAN UCO REACH 100 INR?
Contents
SUN PHARMA IN RECENT NEWS
- Despite experiencing an IT breach, Sun Pharma reassures that its core systems remain unaffected.
- The fixing of retail prices for 74 drug formulations by drug regulator NPPA has resulted in a mixed performance for pharmaceutical stocks.
SUN PHARMA SHARE PRICE TARGET 2023
| SUN PHARMA SHARE PRICE TARGET 2023 | Maximum Price | Minimum Price |
| March 2023 | ₹965.25 | ₹742.50 |
| April 2023 | ₹1,061.78 | ₹816.75 |
| May 2023 | ₹884.81 | ₹680.63 |
| June 2023 | ₹1,061.78 | ₹816.75 |
| July 2023 | ₹1,274.13 | ₹980.10 |
| August 2023 | ₹1,401.54 | ₹1,078.11 |
| September 2023 | ₹1,471.62 | ₹1,132.02 |
| October 2023 | ₹1,401.54 | ₹1,078.11 |
| November 2023 | ₹1,541.70 | ₹1,185.92 |
| December 2023 | ₹1,726.70 | ₹1,328.23 |
The predicted share price for Sun Pharma in 2023 shows a bullish uptrend with a healthy growth percentage. The maximum and minimum share prices range from ₹1,726.70 to ₹680.63 throughout the year, indicating potential growth of over 100%. The share price is expected to start the year at ₹965.25 in March 2023, with an uptrend throughout the year to reach ₹1,726.70 in December 2023.
The stock’s performance is expected to be bolstered by the company’s diversified portfolio, with a strong focus on research and development to create innovative products in various therapeutic areas. Additionally, Sun Pharma’s expansion in more than 100 countries, along with collaborations with leading global pharmaceutical companies, may attract more investors and drive up the share price.
SUN PHARMA SHARE PRICE TARGET 2024
| SUN PHARMA SHARE PRICE TARGET 2024 | Maximum Price | Minimum Price |
| January 2024 | ₹1,817.58 | 1037.03 |
| February 2024 | ₹2,042.22 | ₹1,701.85 |
| March 2024 | ₹2,149.71 | ₹1,747.73 |
| April 2024 | ₹1,954.28 | ₹1,503.29 |
| May 2024 | ₹1,628.57 | ₹1,252.74 |
| June 2024 | ₹1,954.28 | ₹1,503.29 |
| July 2024 | ₹1,661.14 | ₹1,287.71 |
| August 2024 | ₹1,827.25 | ₹1,450.20 |
| September 2024 | ₹1,918.62 | ₹1,475.86 |
| October 2024 | ₹2,257.20 | ₹1,736.30 |
| November 2024 | ₹2,370.06 | ₹1,823.12 |
| December 2024 | ₹2,417.46 | ₹1,859.58 |
The predicted share price target for Sun Pharma in 2024 shows a positive trend with an expected maximum price of ₹2,417.46 and a minimum price of ₹1,252.74. The year is expected to start with a maximum share price of ₹1,817.58 in January 2024 and end with a maximum share price of ₹2,417.46 in December 2024.
Although there may be fluctuations in the share price throughout the year, the overall trend suggests a positive outlook, with expected growth in revenue and profitability.
CLICK HERE:
ICICI BANK SHARE PRICE TARGET 2023 TO 2030: CAN ICICI REACH 3000 INR?
SUN PHARMA SHARE PRICE TARGET 2025
| SUN PHARMA SHARE PRICE TARGET 2025 | Maximum Price | Minimum Price |
| January 2025 | ₹2,465.81 | ₹1,896.77 |
| February 2025 | ₹2,595.58 | ₹1,996.60 |
| March 2025 | ₹2,725.36 | ₹2,096.43 |
| April 2025 | ₹2,433.36 | ₹1,871.82 |
| May 2025 | ₹2,212.15 | ₹1,701.65 |
| June 2025 | ₹2,433.36 | ₹1,871.82 |
| July 2025 | ₹2,317.49 | ₹1,782.68 |
| August 2025 | ₹2,414.05 | ₹1,856.96 |
| September 2025 | ₹2,534.75 | ₹1,949.81 |
| October 2025 | ₹2,686.84 | ₹2,066.80 |
| November 2025 | ₹2,874.91 | ₹2,211.47 |
| December 2025 | ₹2,932.41 | ₹2,255.70 |
The maximum price target for January 2025 is ₹2,465.81, while the minimum price is ₹1,896.77. The maximum price target is expected to increase steadily, reaching ₹2,932.41 in December 2025, while the minimum price target is also expected to rise, reaching ₹2,255.70. This indicates that the share price is likely to remain bullish in the year 2025. However, it’s important to keep in mind that share prices can be affected by various factors, including market conditions, company performance, and global events, which could impact the growth percentage of Sun Pharma’s stock.
SUN PHARMA SHARE PRICE TARGET 2026 TO 2030
| SUN PHARMA SHARE PRICE TARGET BY | Maximum Price | Minimum Price |
| 2026 | ₹2,052.69 | ₹1,436.88 |
| 2027 | ₹1,744.79 | ₹1,221.35 |
| 2028 | ₹3,140.61 | ₹2,198.43 |
| 2029 | ₹6,451.31 | ₹4,515.92 |
| 2030 | ₹7,184.41 | ₹5,029.09 |
For 2026, the maximum price target is predicted to be around ₹2,052.69, while the minimum price target is around ₹1,436.88. This indicates a potential growth rate of approximately 43% to 67% compared to the minimum price target in 2025. Moving further down the line, the maximum and minimum price targets for 2027 are predicted to be around ₹1,744.79 and ₹1,221.35 respectively. The year 2028 shows a significant jump in price targets, with the maximum and minimum predicted to be around ₹3,140.61 and ₹2,198.43. The year 2029 is predicted to show a substantial increase with a maximum price target of ₹6,451.31 and a minimum price target of ₹4,515.92. Finally, for 2030, the maximum price target is predicted to be around ₹7,184.41, while the minimum price target is around ₹5,029.09. These predictions suggest a bullish trend in the coming years, with a potential for substantial growth in Sun Pharma’s share prices.
CLICK HERE TO KNOW:
BANDHAN BANK SHARE PRICE TARGET 2023 TO 2030: CAN BANDHAN BANK REACH 1000 INR?
FINANCIAL STRENGTH OF SUN PHARMA (2018 TO 2022)
| ANNUAL | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| Total Revenue | 39,576.00 | 34,333.66 | 33,473.48 | 30,091.40 | 27,254.30 |
| Total Revenue Growth (%) | 15.27 | 2.57 | 11.24 | 10.41 | -14.65 |
| Total Expenses | 30,527.86 | 27,228.15 | 28,203.25 | 25,066.82 | 22,824.82 |
| Total Expenses Growth (%) | 12.12 | -3.46 | 12.51 | 9.82 | -0.26 |
| Profit after Tax (PAT) | 3,272.73 | 2,903.82 | 3,764.93 | 2,665.42 | 2,161.55 |
| PAT Growth (%) | 12.70 | -22.87 | 41.25 | 23.31 | -68.96 |
| Operating Profit Margin (%) | 23.73 | 21.63 | 16.97 | 19.19 | 18.72 |
| Net Profit Margin (%) | 8.46 | 8.66 | 11.46 | 9.17 | 8.18 |
| Basic EPS (₹) | 13.60 | 12.10 | 15.70 | 11.10 | 9.00 |
Sun Pharma has been showing consistent growth in its financials over the past five years, with its revenue increasing steadily from ₹27,254.30 crores in FY 2018 to ₹39,576.00 crores in FY 2022, marking a growth of 15.27%. The company’s total expenses have also increased in line with the revenue, with a growth rate of 12.12% from FY 2021 to FY 2022. Despite the increase in expenses, the company has managed to maintain a healthy operating profit margin of 23.73% in FY 2022, indicating its efficient cost management. The net profit margin for FY 2022 stands at 8.46%, which is slightly lower than the previous year. However, the company has recorded a PAT of ₹3,272.73 crores in FY 2022, which marks a growth of 12.70% from the previous year. The Basic EPS for FY 2022 is ₹13.60, which is also an improvement from the previous year. Overall, Sun Pharma has been performing well with steady revenue and profit growth, despite facing challenges in the past.
CLICK HERE FOR MORE:
Emergency Credit Line Guarantee Scheme
FAQ’s
The maximum share price target of Sun Pharma in 2028 is Rs. 3140.61
The maximum share price target of Sun Pharma in 2029 is Rs. 6451.31
The maximum share price target of Sun Pharma in 2030 is Rs. 7184.51
CONCLUSION: SUN PHARMA
According to Sun Pharma’s financial filings for the previous five years, both its sales and profitability have consistently increased. Positive signs of the company’s financial health include the 15.27% revenue growth rate in FY2022, as well as the 12.70% PAT growth rate during the same fiscal year. Nevertheless, the operational profit margin increased steadily over time, reaching 23.73% in FY2022. A long-term investment in Sun Pharma shares may prove profitable due to the company’s financial stability and growth prospects. But before making a choice, it is crucial to carry out more investigation and study, just like with any investment.
